Request Demo
Last update 01 Jun 2025
Anti-BCMA and CD19 CART(Anhui Provincial Hospital)
Last update 01 Jun 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms SCAR02 |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Related
3
Clinical Trials associated with Anti-BCMA and CD19 CART(Anhui Provincial Hospital)NCT06973356
An Exploratory Clinical Study of Anti-CD19/BCMA CAR Gene Vector Injection (LCAR1901) for the Treatment of Relapsed and Refractory Immune Thrombocytopenia
NCT06961669
An Early Exploratory Clinical Study of Enhanced Autologous CAR-T Cell Injection (ECAR01) Targeting CD19 and BCMA in Patients With Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma
NCT06503224
An Exploratory Clinical Study of a Fourth-generation Autologous CAR-T Cell Injection (SCAR02) Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
100 Clinical Results associated with Anti-BCMA and CD19 CART(Anhui Provincial Hospital)
Login to view more data
100 Translational Medicine associated with Anti-BCMA and CD19 CART(Anhui Provincial Hospital)
Login to view more data
100 Patents (Medical) associated with Anti-BCMA and CD19 CART(Anhui Provincial Hospital)
Login to view more data
100 Deals associated with Anti-BCMA and CD19 CART(Anhui Provincial Hospital)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Purpura, Thrombocytopenic, Idiopathic | Clinical | China | 16 May 2025 | |
| B-Cell Leukemia | Clinical | China | 16 Apr 2025 | |
| Pre B-cell acute lymphoblastic leukemia | Clinical | China | 16 Apr 2025 | |
| Refractory Multiple Myeloma | Clinical | China | 16 Apr 2025 | |
| Rheumatoid Arthritis | Clinical | China | 09 Apr 2024 | |
| Scleroderma, Systemic | Clinical | China | 09 Apr 2024 | |
| Systemic Lupus Erythematosus | Clinical | China | 09 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free